Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2014

Das Thakur Meghna, Stuart Darrin D

Abstract excerpt

The RAS-RAF-MEK (MAP-ERK kinase)-ERK (extracellular signal-regulated kinase) pathway plays a central role in driving proliferation, survival, and metastasis signals in tumor cells, and the prevalence of oncogenic mutations in RAS and BRAF and upstream nodes makes this pathway the focus of significant oncology drug development efforts. This focus has been justified by the recent success of BRAF and MEK inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Signal Transduction

Share to Translational Research, Biomedical

Share to Treatment Outcome

Source

Identifiers

PMID: 24352648
DOI: 10.1158/1078-0432.CCR-13-0103

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.PMID 24352648Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Resistance to BRAF-targeted therapy in melanoma.Semantic proximity Read ↗

BRAF Gene and Melanoma: Back to the Future.Semantic proximity Read ↗

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceSemantic proximity Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.